Antivirals can prevent bad cases of H1N1
ANTIVIRAL medicines can prevent severe H1N1 flu and should be given to pregnant women, very young children and people with underlying medical problems who fall ill, a World Health Organization official said yesterday.
"In at-risk groups, in order to prevent progression to severe disease, antivirals need to be administered early," said Nikki Shindo of the WHO's global influenza program.
"This also holds for otherwise healthy people who show progressive symptoms. Patients with pneumonia also should be treated with antiviral medicines, antibiotics, oxygen, and balanced fluid management."
The WHO has previously said there were only "isolated and infrequent" cases of resistance to antivirals like osetamivir, marketed by Switzerland's Roche Holding.
Shindo said the virus had not mutated and research undertaken since H1N1 emerged earlier this year had shown that antiviral drugs were safe in pregnant women, children under the age of two, and other vulnerable patients.
"We are changing the recommendations to make (them) more explicit about early treatment," she said.
Many doctors have been waiting for laboratory confirmation that patients are infected with H1N1, and not something else, before administering antiviral drugs.
Shindo said doctors in places where the virus is known to be circulating "should not wait for the laboratory information" to start such treatment in high-risk groups.
But she also stressed that healthy people should not take antiviral drugs unless their symptoms worsen quickly.
Hospitals in Afghanistan, Ukraine and Moldova have reported being overwhelmed with patients with H1N1 flu, said Shindo, who suggested early antiviral treatment could help ease this strain.
"In at-risk groups, in order to prevent progression to severe disease, antivirals need to be administered early," said Nikki Shindo of the WHO's global influenza program.
"This also holds for otherwise healthy people who show progressive symptoms. Patients with pneumonia also should be treated with antiviral medicines, antibiotics, oxygen, and balanced fluid management."
The WHO has previously said there were only "isolated and infrequent" cases of resistance to antivirals like osetamivir, marketed by Switzerland's Roche Holding.
Shindo said the virus had not mutated and research undertaken since H1N1 emerged earlier this year had shown that antiviral drugs were safe in pregnant women, children under the age of two, and other vulnerable patients.
"We are changing the recommendations to make (them) more explicit about early treatment," she said.
Many doctors have been waiting for laboratory confirmation that patients are infected with H1N1, and not something else, before administering antiviral drugs.
Shindo said doctors in places where the virus is known to be circulating "should not wait for the laboratory information" to start such treatment in high-risk groups.
But she also stressed that healthy people should not take antiviral drugs unless their symptoms worsen quickly.
Hospitals in Afghanistan, Ukraine and Moldova have reported being overwhelmed with patients with H1N1 flu, said Shindo, who suggested early antiviral treatment could help ease this strain.
- About Us
- |
- Terms of Use
- |
-
RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔$粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.